A Phase Ib/II, Multicenter Study of LJM716 in Combination With Cetuximab in Patients With Platinum-pretreated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Trial Profile

A Phase Ib/II, Multicenter Study of LJM716 in Combination With Cetuximab in Patients With Platinum-pretreated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Elgemtumab (Primary) ; Cetuximab
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 20 Apr 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
    • 20 Apr 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 11 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top